Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Biotechnology

Healthcare
$75.95 +0.46%

+$0.29 today

Market cap
$3.74B
Beta
0.51
P/E (TTM)
-55.9
EPS (TTM)
-$1.12
52W Low $38.51High $85.25

Volume 0.45M

Average 0.61M

TARS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Tarsus Pharmaceuticals, Inc.NASDAQ: TARS

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$663.71M, compared with -$12.19M a year earlier. Trailing-twelve-month EBITDA was -$686.8M.

Context

  • EBITDA amounted to 11.9% of revenue in FY2025, down 46.3 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$621.82M (-1059.9%) for the fiscal year ending Dec 2026, a slowdown from the +49.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$663.71M-5134.8% QoQ
Last fiscal yearDec 2025
-$53.61M+49.7% YoY
LTMSep 2026
-$686.8M-845.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5347.0%-150.3%+5196.7 pp
1 year+49.7%-1059.9%-1109.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(53.61M) USD
Year-over-year change
+49.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TARS compares with its peers on the latest reported figures

  • TARS's LTM Sep 2026 EBITDA of -$686.8M is the lowest of the 6 companies compared; the peer median is -$1.98M.
  • Its year-over-year change of -845.4% is the lowest of 5, against a peer median of +82.7%.
  • EBITDA amounts to 100.7% of revenue for TARS, versus a peer median of 11.2%.
TARS Competitors Peer median
EBITDA for TARS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$43.43M +163.2%—9.4%
HROWHarrow Health, Inc.LTM Mar 2026$31.47M +78.4%—11.7%
SLGLSol-Gel Technologies Ltd.LTM Mar 2026-$1.98M +85.8%—10.7%
TTRXTurn Therapeutics Inc.LTM Mar 2026-$3.79M ———
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-$11.36M +79.6%—30.6%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-$686.8M -845.4%—100.7%
Peer median (excluding TARS) -$1.98M+82.7%—11.2%

Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue57.03M25.82M17.45M182.95M451.36M
Cost of Revenue2.08M955K1.59M12.83M30.68M
Gross Profit54.95M24.86M15.85M170.13M420.68M
Gross Margin96.4%96.3%90.9%93.0%93.2%
Research & Development41.71M42.62M50.31M53.39M64.32M
Selling, General & Admin25.4M44.95M108.7M237.31M427.32M
Operating Expenses67.11M87.57M159.01M290.7M491.65M
Depreciation & Amortization312K326K877K1.23M1.82M
EBITDA(13.46M)(59.71M)(131.67M)(106.48M)(53.61M)
EBITDA Margin-23.6%-231.3%-754.7%-58.2%-11.9%
Operating Income(12.16M)(62.71M)(143.16M)(120.57M)(70.97M)
Operating Margin-21.3%-242.9%-820.5%-65.9%-15.7%
Interest Income36K3.5M10.34M15.01M15.75M
Interest Expense02.06M3.23M7.45M8.94M
Other Income / Expenses(1.62M)617K7.27M5.02M6.61M
Income Before Tax(13.77M)(62.1M)(135.89M)(115.55M)(64.36M)
Pre-Tax Margin-24.1%-240.5%-778.9%-63.2%-14.3%
Income Tax Expense55K(4K)002.06M
Net Income(13.83M)(62.09M)(135.89M)(115.55M)(66.42M)
Net Margin-24.2%-240.5%-778.9%-63.2%-14.7%
EPS (Basic)(0.67)(2.52)(4.62)(3.07)(1.59)
EPS (Diluted)(0.67)(2.52)(4.62)(3.07)(1.59)
Weighted Avg Shares20.55M24.62M29.38M37.6M41.78M
Weighted Avg Shares (Diluted)20.55M24.62M29.38M37.6M41.78M

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Intrinsic Alpha fair value

Locked

Current Price

$75.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.